Mr. Thomas Smeenk reports

HEMOSTEMIX CLOSES PRIVATE PLACEMENT OF $469,366

Hemostemix Inc. has closed a non-brokered private placement in the amount of $469,366 by the issuance of 3,911,385 common shares at 12 cents each, subject to the approval of the TSX Venture Exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

Per Policy 4.1, the subscriber is arm's length to the company and is not a related party to the company at the time of disclosure.

The use of proceeds will be allocated to general working capital purposes, supporting the company's continuing operational expenses and business development activities.

The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 60 per cent in the CLTI patient population, UBC and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.